1. Home
  2. PERF vs CRDF Comparison

PERF vs CRDF Comparison

Compare PERF & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Perfect Corp.

PERF

Perfect Corp.

HOLD

Current Price

$1.49

Market Cap

151.8M

Sector

Technology

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$1.94

Market Cap

130.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PERF
CRDF
Founded
2015
1999
Country
Taiwan
United States
Employees
N/A
33
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
151.8M
130.7M
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
PERF
CRDF
Price
$1.49
$1.94
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$9.63
AVG Volume (30 Days)
112.1K
806.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.37
EPS
N/A
N/A
Revenue
N/A
$365,993.00
Revenue This Year
$16.32
N/A
Revenue Next Year
$12.83
N/A
P/E Ratio
$26.42
N/A
Revenue Growth
N/A
49.61
52 Week Low
$1.24
$1.48
52 Week High
$2.67
$4.56

Technical Indicators

Market Signals
Indicator
PERF
CRDF
Relative Strength Index (RSI) 46.57 52.03
Support Level $1.35 $1.51
Resistance Level $1.61 $2.41
Average True Range (ATR) 0.10 0.11
MACD 0.00 0.08
Stochastic Oscillator 52.50 79.61

Price Performance

Historical Comparison
PERF
CRDF

About PERF Perfect Corp.

Perfect Corp is engaged in the beauty and fashion tech revolution, providing omni-channel integrated solutions. The company runs a hybrid business model of direct consumer business (B2C business) and enterprise business (B2B business). For B2C businesses, the company offers six mobile apps under the "YouCam" suite, along with one online editing service tool, YouCam Online Editor, featuring AI and AR technologies. For B2B businesses, the company offers AI and AR-powered solutions tailored for the beauty and fashion industry. Geographically, the company has a presence in the United States, Americas-other, France, Japan, and Others. The company generates the majority of its revenue from the United States.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: